Capsule Factory Project Onboarding: RFQ Questions to Answer Before Requesting Samples

Direct Answer

A strong capsule factory project onboarding RFQ checklist should be completed before a buyer requests samples, because a sample is only useful when its formula, shell, mold, packaging, documentation, and production route are already defined. For serum capsules, the critical questions are not limited to appearance or sensory feel. Buyers must confirm capsule shell material, fill viscosity, target fill weight, oxidation controls, mold availability, packaging compatibility, storage conditions, stability protocol, labeling documents, and the conditions under which the sample can be scaled.

This diligence is particularly important when a group is replacing a supplier after a quality incident, responding to a failed third-party audit, or adding a capsule format that its incumbent factory cannot produce. The objective is to establish whether the proposed ODM can reproduce the sample at commercial scale under controlled specifications. The serum capsules manufacturer should therefore receive a controlled RFQ pack, not an informal request for a catalogue sample.

Key Takeaways for Private Label Buyers

• Define the intended serum formula, active system, target viscosity, fill weight, shell material, and use-by period before comparing quotations.
• Require evidence that the same capsule mold, filling method, and packaging configuration can support both sampling and commercial production.
• Assess oxidation, leakage, shell aging, heat, and humidity risks through a documented stability and transport-testing plan.
• Separate sample approval from production approval; confirm batch records, raw-material certificates, artwork controls, and release testing requirements in the RFQ.
• Request clear MOQ, pilot scope, capacity reservation, shipment conditions, and change-control commitments before approving a launch schedule.

Buyer Context

Serum-capsule sourcing creates a different risk profile from conventional pump or dropper packaging. A retinol capsule may require protection from oxygen, light, and repeated handling. A facial oil capsule may remain chemically stable but create leakage or seal-integrity concerns when exposed to heat during transit. An eye serum capsule requires accurate dosing and a shell that opens cleanly without creating an unacceptable application experience. Cleansing oil capsules and hair oil capsules may require a different fill profile, shell behavior, and packaging geometry.

For a multinational brand, these variables affect more than product development. They influence artwork declarations, regional notification files, transport qualification, complaint investigation, and recall exposure. Procurement teams should also determine whether the proposed factory can provide an auditable certificate trail for each ingredient and packaging component, including origin, batch identification, allergen information where applicable, and conformity documents.

The issue becomes more material when a brand is diversifying its supplier pool after an unexpected plant shutdown, a labor or compliance finding, or a major batch deviation. A new serum capsule product should be evaluated as a controlled manufacturing transfer. The sample must demonstrate the intended formula and packaging route, while the factory must demonstrate repeatability, documentation discipline, and resilience under the buyer’s escalation procedures.

For groups with ESG requirements, the RFQ should also identify the factory’s audit status, wastewater controls, energy and emissions records, worker-management systems, and subcontracting practices. These are qualification gates, not post-award administrative details. The ISO 22716 cosmetic GMP standard provides a useful reference point for manufacturing controls, while the EU Cosmetics Regulation framework helps buyers structure documentation expectations for European distribution.

Ingredient review should be connected to the destination market. Buyers can use the European Commission’s CosIng ingredient database as an initial regulatory reference, but the factory should still confirm the final formula, claims support, product information file inputs, and market-specific labeling responsibilities.

Retinol serum capsules illustrate why early technical alignment matters. The supplier should state the retinoid form, concentration, carrier system, light and oxygen controls, compatibility limits, and the stability evidence available for the proposed packaging. Buyers should not treat a visually attractive capsule as evidence of formula robustness.

Encapsulated retinol skincare may also require different handling instructions from facial oil capsules. Where a vegan shell is required, the buyer should confirm the polymer or hydrocolloid system, moisture sensitivity, sealing behavior, storage range, and whether the proposed shell has been tested with the intended fill. Shell selection is a technical and commercial decision because it can affect mold performance, opening behavior, packaging compatibility, and shipment loss.

Capsule Formula, Shell, Mold, and Packaging Factors

Formula and fill profile. The RFQ should state whether the product is an anhydrous facial oil, a water-containing serum, a suspension, or another defined system. The buyer should request target viscosity, density, fill weight tolerance, active concentration, fragrance or essential-oil content, and container-closure compatibility. A supplier that quotes a unit price without confirming these inputs has not yet established a reliable manufacturing basis.

Shell material and mold. Confirm whether the capsule uses gelatin or a vegan capsule shell, together with shell thickness, colorant system, plasticizer, moisture target, and storage sensitivity. Ask whether the mold is an existing standard format or a custom softgel mold, who owns the tooling, and how changes are approved. For a private label launch, tooling ownership and mold access should be written into the commercial and quality agreements.

Fill weight and leakage control. The factory should describe in-process weight checks, seal inspection, rejected-unit handling, and the investigation process for leaking or deformed capsules. Fill weight affects consumer dosing, carton counts, cost modeling, and claims substantiation. It should therefore appear on the approved specification rather than remain a verbal target.

Packaging compatibility. Request compatibility data for blister packaging, jars, trays, and any secondary pouch. The evaluation should cover capsule deformation, shell moisture exchange, oil migration, seal contact, abrasion, light exposure, and transport vibration. A capsule that passes laboratory storage but leaks inside a jar during distribution is not a successful sample.

Storage and stability. The RFQ should define planned storage conditions, accelerated and real-time stability, orientation, sampling intervals, assay or marker testing, appearance checks, odor change, leakage, shell brittleness, and package integrity. Include heat and humidity exposure where the target market or shipping lane requires it. Shipment conditions should specify temperature controls, pallet configuration, protection from direct light, and the escalation process for a temperature excursion.

Documentation and scale-up. Before sample approval, request the ingredient certificate package, packaging specifications, batch coding approach, certificate of analysis format, test methods, and draft manufacturing flow. The buyer should also confirm whether the sample will be produced on the intended commercial line. A laboratory sample made through a different process can create false confidence and later require formula or mold re-engineering.

Private label serum capsules should be assessed against these controls as a complete system. The relevant question is not whether the sample looks acceptable; it is whether the formula, shell, mold, packaging, testing, and documentation can remain aligned through approval, production, and shipment.

Decision Framework Table

ODM Manufacturing Considerations

A useful capsule factory project onboarding RFQ checklist should define what the buyer is approving at each development stage. The first laboratory sample may establish sensory direction, but it should not automatically become the commercial specification. Record the sample code, ingredient list, fill color, odor, viscosity range, capsule dimensions, target unit mass, shell composition, and acceptable appearance. Approval should be written and linked to a retained reference sample so that later revisions remain traceable.

For fill formula customization, tell the ODM which attributes are fixed and which can be adjusted. Relevant inputs include ingredient origin preferences, excluded substances, fragrance level, intended skin feel, color limits, antioxidant system, and target market. A thin facial oil and a concentrated eye serum can behave differently during encapsulation even when their ingredient lists appear similar. Ask the factory to report fill-flow behavior, settling or separation observations, and the measured variation among finished capsules.

Shell selection should cover animal-derived gelatin, plant-based alternatives, colorants, opacity, flexibility, and any market-specific claims. Request the shell material specification and supporting certificate rather than relying on a website description. Buyers evaluating plant-derived formats can also review the supplier’s vegan skincare capsule capabilities. The fill and shell must be assessed together because solvents, fragrance components, and certain oils can change shell strength over time.

Mold selection affects dose, product presentation, packing density, and machine setup. Confirm whether an existing shape can meet the required capacity before commissioning a custom design. The RFQ should state who controls the tooling, whether it can be used for other customers, how replacement tooling is approved, and what happens to it if production transfers. For sensitive actives, such as those used in retinol capsule programs, shape decisions should also consider surface-area exposure and the protection provided by the final pack.

Packaging trials must use production-intent components. For jars, assess closure seal, headspace, capsule movement, dispensing, and deformation under stacking. For blisters, verify cavity dimensions, sealing conditions, lidding integrity, and capsule release. Stability protocols should include defined time points under normal and accelerated environments, with observations for odor, color, shell texture, mass change, and fill uniformity.

Separate the MOQ for development samples, qualification batches, first commercial production, packaging decoration, and repeat orders. Also request draft INCI labeling, allergen or fragrance declarations where applicable, batch coding format, certificate of analysis fields, safety documentation, and country-of-origin records. For EU-bound cosmetics, ingredient naming can be screened through the European Commission’s CosIng ingredient database, while final compliance must be assessed under the EU Cosmetics Regulation framework.

Shipment terms should define carton configuration, pallet limits, storage range, dispatch release records, transport mode, and responsibility for damaged or delayed goods. Request a route-risk plan when capsules will cross hot climates or remain in uncontrolled freight hubs.

Common Problems or Failure Cases

Shell brittleness: Capsules can crack during counting, packing, or consumer handling when moisture balance is unsuitable. A factory should compare retained samples across storage conditions and document breakage during line handling.

Sticking or deformation: Capsules may adhere to one another or flatten against jar walls because of shell composition, residual surface material, high temperature, or excessive compression inside the pack. Production-intent jars and closures should be tested before artwork is finalized.

Fill separation: Suspended ingredients may settle or produce visible gradients. Ask whether the formula is a true solution, dispersion, or suspension and how the bulk is kept uniform during filling. Finished-capsule mass data alone will not prove ingredient uniformity.

Leakage: Weak seals, incompatible fill components, incorrect machine settings, or mechanical damage can release serum. The investigation should distinguish seal failure from shell puncture and include batch location, defect rate, photographs, and retained samples.

Fragrance sensitivity: Fragrance materials can change odor, shell flexibility, or fill color. A fragrance accepted in a conventional bottled serum should not be assumed suitable for a soft capsule without testing.

Packaging deformation: Thin jars, poorly fitted liners, or blister cavities with insufficient clearance may distort during filling, sealing, warehousing, or transit. Final approval should use decorated components from the intended packaging converter.

Supplier Checklist

• Obtain the full legal factory name, manufacturing address, audit scope, and current cosmetics certificate set.
• Confirm shell material, colorant system, fill viscosity range, target unit mass, and allowable variation.
• Review ingredient origin records, lot traceability, incoming-test methods, and approved alternate sources.
• Define sample rounds, approval authority, retained references, change control, and deviation handling.
• Confirm mold status, tooling-use restrictions, maintenance responsibility, and replacement procedure.
• Require jar or blister trials using final materials, dimensions, decoration, and closure configuration.
• Approve stability endpoints for appearance, odor, fill consistency, shell strength, and seal integrity.
• Separate formula, capsule, packaging, and decoration minimums in the quotation.
• Review labeling files, batch documents, release criteria, complaint workflow, and recall traceability.
• Document shipment range, pallet pattern, freight route, release records, and damage-claim responsibility.

If an incumbent supplier has failed an unannounced audit, request evidence that corrective actions are operating in practice rather than accepting a certificate alone. Buyers working under a corporate carbon-neutrality strategy should also request site-level energy, emissions, wastewater, and independent verification records relevant to the capsule production location.

FAQ

Can a factory guarantee that our core formula will never be leaked?

No credible supplier can promise absolute zero risk. Require role-based system access, segregated customer project folders, controlled formula downloads, physical access restrictions, confidentiality terms, access logs, employee training, and a documented response process. Verify these controls during the audit instead of relying only on an NDA.

How can a strategic buyer secure supply during global raw-material shortages?

Negotiate allocation rules before a shortage occurs. The agreement should identify critical materials, approved alternate sources, reserved inventory, forecast obligations, lead-time alerts, and priority criteria. Ask for evidence that alternates have passed formula, shell, and stability assessment before substitution.

How do we verify that factory workers are treated fairly?

Review recent independent social-audit findings together with payroll samples, age-verification records, working-hour data, overtime consent, grievance channels, and corrective-action closure. Reserve the right to conduct an unannounced audit and interview workers privately. A certificate without supporting records is insufficient.

What should be frozen when a capsule sample is approved?

Freeze the formula revision, shell specification, mold code, target unit mass, color and odor standards, packaging components, test methods, and acceptance limits. Any later change should require documented buyer review.

Why can the capsule MOQ differ from the packaging MOQ?

Capsule production, printed jars, blister materials, cartons, and decorative processes may each have separate setup thresholds. Ask the supplier to show each minimum independently and explain how unused packaging inventory will be stored, owned, and reconciled.

Which documents should accompany commercial batches?

The agreed release pack may include a certificate of analysis, batch identification, manufacturing and expiry information, ingredient documentation, quantity reconciliation, packaging inspection results, and shipping records. Required fields should be approved during onboarding rather than after production.

References

• European Commission CosIng ingredient database
• European Commission cosmetics legislation and sector framework
• Capsule skincare production lead-time and documentation questions